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Abstract
The heterogeneity, mobility and complexity of glycans in glycoproteins have been, and currently remain, significant challenges in
structural biology. These aspects present unique problems to the two most prolific techniques: X-ray crystallography and cryo-elec-
tron microscopy. At the same time, advances in mass spectrometry have made it possible to get deeper insights on precisely the
information that is most difficult to recover by structure solution methods: the full-length glycan composition, including linkage
details for the glycosidic bonds. The developments have given rise to glycomics. Thankfully, several large scale glycomics initia-
tives have stored results in publicly available databases, some of which can be accessed through API interfaces. In the present work,
we will describe how the Privateer carbohydrate structure validation software has been extended to harness results from glycomics
projects, and its use to greatly improve the validation of 3D glycoprotein structures.
Introduction
Glycosylation-related processes are prevalent in life. The
attachment of carbohydrates to macromolecules extends the
capabilities of cells to convey significantly more information
than what is available through protein synthesis and the expres-
sion of the genetic code alone. For example, glycosylation is
used as a switch to modulate protein activity [1]; glycosylation
plays a crucial part in folding/unfolding pathways of some pro-
teins in cells [2,3]; the level of N-glycan expression regulates
the adhesiveness of a cell [4]; glycosylation also plays a role in
immune function [5] and cellular signalling [5,6]. At the fore-
front, glycosylation plays a significant role in influencing pro-
tein–protein interactions. For example, the influenza virus uses
the haemagglutinin glycoprotein to recognise and bind sialic
acid decorations of human cells in the respiratory tract [7].
Glycosylation is also used by pathogens to evade the host’s
immune system via glycan shields [8-10], and thereby to delay
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Figure 1: Comparison of the glycan features in electron density maps over a range of resolutions from selected glycoprotein structures (PDB entries:
6RI6 [19]; 6MZK [20]; 4O5I [21]). The electron density maps were obtained with X-ray crystallography. The data resolution and PDB entry IDs associ-
ated with the structures have been directly annotated on the structure. Left: A high-resolution example where monosaccharides and the conforma-
tions can be elucidated; middle: A medium resolution example where the identification starts to become difficult; right: A low-resolution example for
which all prior knowledge must be used. Despite coming from different glycoprotein structures, the glycan has the same composition, and thus is
assigned a unique GlyTouCan ID of G15407YE.
an immune response [11]. The structural study of these glycan-
mediated interactions can provide unique insight into the molec-
ular interplay governing these processes. In addition, it can
provide structural snapshots in atomistic detail that can be used
to generate molecular dynamics simulations describing a wider
picture underpinning glycan and protein interactions [12].
Unfortunately, significant challenges have affected the determi-
nation of glycoprotein structures for decades and have had a
detrimental impact on the quality and reliability of the pro-
duced models. Anomalies have been reported regarding carbo-
hydrate nomenclature [13], glycosidic linkage stereochemistry
[14] and torsion [15,16], and most recently, ring conformation
[17]. Most of these issues have now been addressed as part of
ongoing efforts to provide better software tools for structure de-
terminations of glycoproteins, although the most difficult cases
remain hard to solve. Chiefly among these is the scenario where
the experimentally resolved electron density map provides evi-
dence of glycosylation, without enough resolution to derive
definite and comprehensive details about the structural compo-
sition of the oligosaccharides (Figure 1). Glycan microhetero-
geneity and the lack of carbohydrate-specific modelling tools
have often been named as the principal causes for these issues
[18].
Heterogeneity of glycoproteins
Unlike protein synthesis, which is encoded in the genome and
follows a clear template, glycan biosynthesis is not template-
directed. A single glycoprotein will exist in multiple possibili-
ties of products that can emerge from the glycan biosynthesis
pathways, and these are known as glycoforms [22]. More
specifically, the variation can appear in terms of which poten-
tial glycosylation sites are occupied at any time – macrohetero-
geneity – or variations in the compositions of the glycans added
to specific glycosylation sites – microheterogeneity. This varia-
tion in the microheterogeneous composition patterns arises due
to the competition of glycan-processing enzymes in biosynthe-
sis pathways [23].
Implications for the structure determination of
glycoproteins
Several experimental techniques can be used to obtain 3D struc-
tures of glycoproteins: X-ray crystallography (MX, which
stands for macromolecular crystallography), nuclear magnetic
resonance spectroscopy (NMR) and electron cryomicroscopy
(cryo-EM). As of publication date, the overwhelming majority
of glycoprotein structures have been solved using MX [24,25].
The biggest bottleneck in MX is the formation of crystals of the
target macromolecule or complex. The quality of the crystal
directly determines the resolution – a measure of the detail in
the electron density map. Homogenous samples at high concen-
trations are required to produce well-diffracting crystals [26].
Samples containing glycoprotein molecules do not usually
fulfill this criterion. More often than not, MX falls short at elu-
cidating carbohydrate features in glycoproteins due to glycosy-
lated proteins being inherently mobile and heterogeneous [22].
Moreover, oligosaccharides often significantly interfere with
the formation of crystal contacts that allow the formation of
well-diffracting crystals. Because of this, glycans are often trun-
cated in MX samples to aid crystal formation [27].
In cryo-EM, samples of glycoproteins are vitrified at extremely
low temperatures rather than crystallised, as in MX. The rapid
cooling of the sample allows to capture snapshots of the mole-
cules at their various conformational states, and thus potentially
maintaining glycoprotein states more closely to their native
environments in comparison to crystallography [28]. Neverthe-
less, cryo-EM is still not an end-all solution to solving glyco-
protein structures: the flexible and heterogeneous nature of
glycans still has an adverse effect on the quality of the data,
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affecting the image reconstruction [29]. Moreover, due to the
low signal-to-noise ratio, the technique works more easily with
samples of a high molecular weight; this situation, however, is
evolving rapidly, with reports of sub-100 kDa structures
becoming more frequent lately [30,31]. Crucially, MX and
cryo-EM can complement each other to counteract issues that
both face individually [32].
The two techniques produce different information – electron
density (MX) or electron potential (cryo-EM) maps – but the
practical considerations in terms of the atomistic interpretation
hold true for both: provided that at least the secondary struc-
tural features can be resolved in a 3D map, a more or less com-
plete atomic model will be expected as the final result of the
study. Modelling of carbohydrates into 3D maps can be more
complex than modelling proteins [33], although recent advances
in software are closing the gap [34-36]. However, to date it
remains true that most model building software is protein-
centric [15]. As a consequence, the glycan chains in glyco-
protein models that have been elucidated before recent develop-
ments in carbohydrate validation and modelling software tend
to contain a significant amount of errors: wrong carbohydrate
nomenclature [13], biologically implausible glycosidic linkage
stereochemistry [14], incorrect torsion [15,16], and unlikely
high-energy ring conformations [17]. Early efforts in the valida-
tion of carbohydrate structures saw the introduction of online
tools such as PDB-CARE [37] and CARP [16]; more recently,
we released the Privateer software [24], which was the first
carbohydrate validation tool available as part of the CCP4i2
crystallographic structure solution pipeline [38]. In its first
release, Privateer was able to perform stereochemical and con-
formational validation of pyranosides, analyse the glycan fit to
electron density map and offered tools for restraining a mono-
saccharide minimal-energy conformation.
While these features were recognised to address some long-
standing needs in carbohydrate structure determination [39,40],
significant challenges remain, particularly in the scenario where
the glycan composition cannot be ascertained solely from the
three-dimensional map. Unfortunately, this problematic
situation happens frequently, especially in view of the fact that
the median resolution for glycoproteins (2.4 Å) is lower than
that of non-glycosylated – potentially including fully deglyco-
sylated – proteins (2.0 Å) [41]. To date, only one publicly avail-
able model building tool has attacked this issue: the Coot soft-
ware offers a module that will build some of the most common
N-linked glycans in a semiautomated fashion [34]. Indeed, the
Coot module was built around the suggestion that only the most
probable glycoforms should be modelled unless prior know-
ledge of an alternative glycan composition exists in the form of,
e.g., mass spectrometry data [14].
Harnessing glycomics and glycoproteomics
results to inform glycan model building
Current methods used to obtain accurate atomistic descriptions
of molecules fall short in dealing with the heterogeneity of
glycoproteins. However, there are other methods that have been
proven to successfully tackle the challenges posed by glycan
heterogeneity, with mass spectrometry emerging as the one with
the most relevance due to the ability to elucidate the complete
composition descriptions of individual oligosaccharide chains
on glycoproteins [42].
The mass spectrometric analysis of glycosylated proteins can be
with (glycomics) or without (glycoproteomics) the release of
oligosaccharides from the glycoprotein. Usually, glycomics and
glycoproteomics experiments are carried out together to obtain
a complete description of the glycoprotein profile. Glycomics
experiments are required to distinguish stereoisomers and the
linkage information in order to obtain a full structural descrip-
tion about a glycan, whereas glycoproteomics are required to
establish the glycan variability and occupancy at the glycosyla-
tion sites of the protein [43]. Typically, these analyses are based
on mass spectrometry techniques, such as electrospray ioniza-
tion mass spectrometry (ESIMS) and matrix-assisted laser de-
sorption ionization MS (MALDIMS) [43]. Mass spectrometry
techniques are best suited for the determination of the composi-
tion of monosaccharide classes and the chain length. However,
the in-depth analysis of a glycan typically requires the integra-
tion of complementary analytic techniques, such as nuclear
magnetic resonance (NMR) and capillary electrophoresis (CE).
Nevertheless, depending on the sample, advanced mass spec-
trometry techniques can be used to counteract the need for
complementary analytic techniques. One of the examples
of this is tandem mass spectrometry, where the glycan
fragmentation is controlled to obtain the identification of the
glycosylation sites and a complete description of the glycan
structure compositions, including linkage and sequence infor-
mation [44]. Moreover, recent advances in ion mobility mass
spectrometry can now also be used for a complete glycan analy-
sis [45].
The analysis and interpretation of mass spectrometry spectra
produced by glycans is a challenge. Most significantly, in MS
outputs, glycans appear in their generalized composition
classes, i.e., Hex, HexNAc, dHex, NeuAc, etc. The identity
elucidation of generalized unit classes into specific monosac-
charide units (such as Glc, Gal, Man, GalNAc, etc.) requires
prior knowledge of the glycan biosynthetic pathways [46]. Ad-
ditional sources of prior knowledge are bioinformatics
databases that have been curated through the deposition
of experimental data. Bioinformatics databases contain
detailed descriptions of the glycan compositions and
Beilstein J. Org. Chem. 2020, 16, 2523–2533.
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CCSD(CarbBank) – + – + –
LINUCS – + – + –
GlycoSuite – – + + –
BCSDB (+) (+) + + –
LinearCode – – + + –
KCF + + – – –
GlycoCT + + + – –
Glyde-II + + – – –
WURCS 2.0 + + + + +
a“+” Denotes that information can be stored directly without any significant issues, “(+)” denotes that information can be stored indirectly, or that there
are some issues and “–” denotes that information description in the particular sequence format is unavailable. This table is a simplified version of the
one originally published by Matsubara et al. [52].
m/z values of specific glycans, and therefore aiding the process
of glycan annotation [47]. Such bioinformatics databases can
usually be interrogated using textual or graphical notations that
describe the glycan sequence. However, due to the glycan com-
plexity and the incremental nature of the different glycomics
projects, numerous notations have been developed over the
years – e.g., CarbBank [48] utilized CCSD [48] and Euro-
CarbDB [49] and GlycomeDB [50] used GlycoCT [51]
(Table 1).
Thankfully, data from discontinued glycomics projects are not
lost but were integrated into newer platforms, often with novel
notations. One such example is GlyTouCan [53], which uses
both GlycoCT [54] and WURCS [53] as notation languages. As
a result, tools that interconvert between notations were de-
veloped to successfully integrate old data into new platforms.
Additionally, the introduction of tools such as GlycanFormat-
Converter [55] to convert WURCS notations into more human-
readable formats has eased the interpretation of glycan data-
bases.
Significantly, the GlyTouCan project aims to create a public
repository of known glycan sequences by assigning them
unique identification tags. Each identification tag describes a
glycan sequence in the WURCS notation, and this allows to link
specific glycans to other databases, such as GlyConnect [56],
UniCarb-DB [57] and others, any of which are tailored to spe-
cific flavours of glycomics and glycoproteomics experiments.
Ideally, this implementation ends up requiring the user to be
familiar with a single notation – WURCS – used to represent
sequences of glycans.
From glycomics/glycoproteomics to
carbohydrate 3D model building and
validation in Privateer
Many fields, for example pharmaceutical design and engi-
neering [58], molecular dynamics simulations [59] and protein
interaction studies [60], rely upon structural biology to produce
accurate atomistic descriptions of glycoproteins. However, due
to clear limitations of elucidating carbohydrate features in MX/
cryo-EM electron-density maps, structural biologists are likely
to make mistakes. This introduces the possibility of modelling
wrong glycan compositions in glycoprotein models, going as far
as not conforming with general glycan biosynthesis knowledge.
Model building pipelines would therefore greatly benefit from
the ability to validate against the knowledge of glycan composi-
tions elucidated via glycomics/glycoproteomics experiments.
This warrants the need for new tools that are able to link these
methodologies, through an intermediate interconversion library.
A foundation for such interconversion libraries exists in the
form of the carbohydrate validation software Privateer. The
program is able to compute individual monosaccharide confor-
mations from a glycoprotein model, check whether the
modelled carbohydrates atomistic definitions match dictionary
standards as well as output multiple helper tools to aid the pro-
cesses of refinement and model building [24]. Most important-
ly, Privateer already contains methods that allow the extraction
of carbohydrate atomistic definitions to create abstract defini-
tions of glycans in memory, and thus already laying a founda-
tion for the generation of unique WURCS notations and provid-
ing a straightforward access to bioinformatics databases that are
integrated in the GlyTouCan project.
Beilstein J. Org. Chem. 2020, 16, 2523–2533.
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Methods
The algorithm used to generate the WURCS notation in Priva-
teer is based on the description published in Tanaka et al. [61],
with required updates applied from Matsubara et al. [52].
WURCS was designed to deal with the incomplete descriptions
of glycan sequences emerging from glycomics/glycopro-
teomics experiments (i.e., undefined linkages, undefined
residues and ambiguous structures in general). However, the
lack of this detail is unlikely to be supported in “pdb” or
“mmCIF'” format files, which are a standard in structural
biology. As a result, the “atomic ambiguity” capability
(Table 1) is not supported in Privateer’s implementation. More-
over, Privateer’s implementation of WURCS relies on a manu-
ally compiled dictionary that translates the PDB Chemical
Component Dictionary [62] three-letter codes of carbohydrate
monomer definitions found in the structure files into WURCS
definitions of unique monomers (described as “UniqueRES”
[52]).
The WURCS notations are generated for all detected glycans
that are linked to protein backbones in the input glycoprotein
model. For every glycan chain in the model, the algorithm
computes a list of all detected monosaccharides that are unique
and stores that information internally in memory. Then, the
algorithm calculates the unit counts in a glycan chain – how
many unique monosaccharides are modelled in the glycan
chain, the total length of the glycan chain and computes the
total number linkages between monosaccharides. After the com-
position calculations are carried out, the algorithm begins the
generation of the notation by printing out the unit counts. Then,
the list of unique monosaccharide definitions in the glycan
chain are printed out by converting the three-letter PDB codes
into WURCS-compliant definitions. Afterwards, each indi-
vidual monosaccharide of the glycan is assigned a numerical ID
according to its occurrence in the list of unique monosaccha-
rides. Finally, the linkage information between monosaccharide
pairs are generated by assigning individual monosaccharides a
unique letter ID according to their position in the glycan chain.
Alongside a unique letter ID, a numerical term is added that de-
scribes a carbon position from which the bond is formed to
another carbohydrate unit. Crucially, the linkage detection in
Privateer does not rely at all on metadata present in the struc-
ture file. Instead, linkages are identified based on the perceived
chemistry of the input model: which atoms are close enough –
but not too close – to be plausibly linked.
The generated WURCS string can then be used to search
whether an individual glycan chain has been deposited in
GlyTouCan. The scan of the repository occurs internally within
the Privateer software, as all the data is stored in a single struc-
tured data file written in JSON format that is distributed
together with Privateer. If the existence of a glycan in the data-
base is confirmed, then the software can attempt to find records
about the sequence on other, more specialised databases (cur-
rently only GlyConnect) to obtain information such as the
source organism, the type of glycosylation and the glycan core
to carry out further checks in the glycoprotein model (Figure 2).
Availability and performance of the algorithm
This new version of Privateer (MKIV) will be released as an
update to CCP4 7.1. To demonstrate the capabilities of the
computational bridge integrated in the newest version of Priva-
teer (for standalone bundles, please refer to privateer branch
“privateerMKIV_noccp4” of GitHub repository with the instal-
lation instructions provided in the README.md file [63]), it
was run on all N-glycosylated structures in the PDB solved
using MX and cryo-EM. The list of structures used in this
demonstration was obtained from Atanasova et al. [18]. The
computational analysis of the demonstration revealed a relative-
ly small proportion of deposited glycoprotein models contain-
ing glycan chains that do not have a unique GlyTouCan acces-
sion ID assigned, raising questions about the provenance of
their structures. Importantly, the majority of the glycan chains
that do have a unique GlyTouCan accession ID assigned
(except for single residues linked to protein backbones), have




As observed in previous studies, glycoprotein models deposited
in the PDB feature flaws ranging from minor irregularities to
gross modelling errors [14,17,41,64]. The automated validation
of minor irregularities was already possible with automated
tools such as pdb-care [37], CARP [65], and Privateer [24].
However, the automated detection of gross modelling errors is
currently a challenge due to the lack of publicly available tools.
Our newly developed computational bridge between structural
biology and glycomics databases makes the detection of gross
modelling errors easier, as demonstrated by the following ex-
amples.
Example 1 – 2H6O
The glycoprotein model (PDB code 2H6O) proposed by
Szakonyi et al. [66] contains 12 glycans, as detected by Priva-
teer. The model became infamous after it sparked the submis-
sion of a critical correspondence published by Crispin et al.
[14]. The article contained a discussion about the proposed
model containing glycans that were previously unreported and
inconsistent with glycan biosynthetic pathways. In particular,
the model contained oligosaccharide chains with Man-(1→3)-
GlcNAc and GlcNAc-(1→3)-GlcNAc linkages, β-galactosyl
Beilstein J. Org. Chem. 2020, 16, 2523–2533.
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Figure 2: A roadmap of the software development project that allows structural biologists to quickly obtain detailed information about specific glycans
in glycoprotein models from glycomics/glycoproteomics databases. The GlyTouCan (https://glytoucan.org/) and GlyConnect (https://
glyconnect.expasy.org/) logos have been reproduced here under explicit permission from their respective authors.













MX 1 16797 0 1% 16797
MX 2 5870 5 90% 5875
MX 3 2550 17 71% 2567
MX 4 1012 21 80% 1033
MX 5 834 72 74% 906
MX 6 460 85 69% 545
MX 7 345 55 77% 400
MX 8 235 25 85% 260
MX 9 164 16 81% 180
MX 10 118 5 92% 123
MX 11 20 5 85% 25
MX 12 8 4 75% 12
MX 13 0 1 0% 1
MX 14 0 0 0% 0
MX 15 2 0 0% 2
MX 16 0 1 0% 1
cryo-EM 1 2080 0 3% 2080
cryo-EM 2 1081 0 98% 1081
cryo-EM 3 439 0 96% 439
cryo-EM 4 143 0 93% 143
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Table 2: Comparison of the successful glycan matches detected by Privateer in the GlyTouCan and the GlyConnect database.a (continued)
cryo-EM 5 146 2 85% 148
cryo-EM 6 70 1 97% 71
cryo-EM 7 45 0 100% 45
cryo-EM 8 26 0 88% 26
cryo-EM 9 15 1 100% 16
cryo-EM 10 16 0 100% 16
cryo-EM 11 4 0 100% 4
cryo-EM 12 1 0 100% 1
cryo-EM 13 1 0 0% 1
aGlycans obtained from the glycoprotein models were elucidated by X-ray crystallography and cryo-EM.
motifs capping oligomannose-type glycans and hybrid-type
glycans containing terminal Man-(1→3)-GlcNAc [14]. More-
over, the proposed model contained systematic errors in the
anomer annotations and carbohydrate stereochemistry. To this
day, there is still no experimental evidence reported for these
types of linkages and capping in an identical context.
The new version of Privateer was run on the proposed model.
WURCS notations were successfully generated for all glycans,
with only 1 glycan chain out of 12 successfully returning a
GlyTouCan ID. Under further manual review of the one glycan
and with help from other validation tools contained in Privateer,
it was found to contain anomer mismatch errors (the three letter
code denoting one anomeric form did not match the anomeric
form reflected in the atomic coordinates). After the anomer
mismatch errors were corrected, the oligosaccharide chain also
failed to return GlyTouCan and GlyConnect IDs. The other 11
chains that failed to return a GlyTouCan ID also contained
flaws, as described previously (Figure 3).
The analysis of this PDB entry highlights the kind of cross-
checks that could be done by Protein Data Bank annotators
upon validation and deposition of a new glycoprotein entry. It
should be recognised that PDB annotators might not necessari-
ly be experts in structural glycobiology. The fact that these
glycans could not be matched to standard database entries
should be enough to raise the question with depositors, and at
the very least write a caveat on a deposited entry where glycans
could not be correctly identified. Furthermore, despite the ex-
ample showing just N-glycosylation, other kinds of glycosyla-
tion are searchable as well, and therefore this tool could shed
much needed light on the validity of models representing more
obscure types of modifications.
Example 2 – 2Z62
Successfully matching the WURCS string to a GlyTouCan ID,
should not be a sole measure of a structure validity. GlyTouCan
is a repository of all potential glycans collected from a set of
databases, with the entries often representing glycans. There-
fore, the correctness of the composition should be critically
validated against the information provided in specialized and
high-quality databases such as GlyConnect [56] and
UniCarbKB [67]. The computational bridge provides direct
search of entries stored in GlyConnect, with plans to expand
this to more databases in the near future.
An example where the sole reliance on the detection of a glycan
in GlyTouCan would not be sufficient is rebuilding of the 2Z62
glycoprotein structure [68] to improve the model quality [41]
(Figure 4). The analysis of the original model generated the
GlyTouCan ID G28454KX, which could not be detected in
GlyConnect. The automated tools used by PDB-REDO slightly
improved the model by renaming one of the fucose residues
from FUL to FUC due to an anomer mismatch between the
three letter code and the actual coordinates of the monomer.
The new model thus generated the GlyTouCan ID G21290RB,
which in turn could be matched to the GlyConnect ID 54. Under
further manual review of mFo-DFc difference density map, a
(1→3)-linked fucose was added, along with additional correc-
tions to the coordinates of the molecule [41]. The newly gener-
ated WURCS notation for the model returned a GlyTouCan ID
of G63564LA, with a GlyConnect ID of 145. The iterative steps
taken to rebuild the glycoprotein model have been portrayed
(Figure 4). Because the data in GlyConnect is approximately
70% manually curated by experts in the field [56], a match of a
specific glycan in this database is likely a valid confirmation of
a specific oligosaccharide composition and linkage pattern
found in nature.
Conclusion
The mirrors of GlyConnect and GlyTouCan were obtained
thanks to the public access to the API commands, which
allowed to create scripts that automated the query of the entries
stored in the databases with relative ease. However, the integra-
tion of additional databases might require support from the
developers of those databases. Support for lipopolysaccharides
Beilstein J. Org. Chem. 2020, 16, 2523–2533.
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Figure 3: N-Linked glycans in Epstein Barr virus major envelope glycoprotein (PDB entry: 2H6O [66]). A) A selection of the glycan chains that failed to
return database IDs with their WURCS sequences extracted from the Privateer CCP4i2 report. B) Glycan chain (right) for which a GlyTouCan and
GlyConnect ID have successfully been matched with the modelling errors present in the model. After manual fixing (left), the WURCS sequence for
the glycan failed to return database IDs. Highlighting in red depicts the locations in WURCS notation where both glycans differ.
and polysaccharides may be added in future, too, owing to the
general purpose of the integrated databases – i.e., they are not
limited to protein glycosylation.
Currently, the generated WURCS strings are matched against
an identical sequence in the database. This means that if a
glycan model has a single modelling mistake, for example, at
Beilstein J. Org. Chem. 2020, 16, 2523–2533.
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Figure 4: An N-linked glycan attached to Asn35 of human Toll-like receptor 4 (A: PDB entry 2z62 [68]). Model iteratively rebuilt by PDB-Redo as
shown in steps B and C [41]. Pictures at the top depict glycoprotein models of the region of interest and electron-density maps of the glycan chain
(grey: 2mFo DFc map, green and red: mFo DFc difference density map). Pictures at the bottom depict the SNFG representations of glycan chains,
their WURCS sequence and accession IDs to relevant databases (taken directly from Privateer's CCP4i2 report).
one end of the chain but is correct elsewhere, the current
version of the software would still fail to return a match. This
issue has been solved in the development version by the incor-
poration of a subtree matching algorithm, which will reveal
modelling mistakes at specific positions of the glycans, and
report these to the user.
Currently, all the developments outlined in this work are acces-
sible exclusively through the Privateer command line interface
and through Coot scripts. In order to facilitate the interaction
with users, a graphical interface to the new functionality will
be provided through the CCP4i2 [38] framework. This new
version of the interface is at the testing stage at the time of
publication.
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